Selective Serotonin Reuptake Inhibitors Inhibit Human Osteoclast and Osteoblast Formation and Function
Jason M Hodge, Yiming Wang, Michael Berk, Fiona M Collier, Tania J Fernandes, Matthew J Constable, Julie A Pasco, Seetal Dodd, Geoffrey C Nicholson, Richard L Kennedy, Lana J Williams
Biological Psychiatry | ELSEVIER SCIENCE INC | Published : 2013
This work was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC).MB has received Grant/Research Support from the National Institutes of Health, Simons Foundation, Cooperative Research Centres for Mental Health, Stanley Medical Research Institute, Medical Benefits Fund, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, Servier, and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, and Pfizer and a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay, and Wyeth.